Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative influenza vaccine and arginine immunonutrition in abdominal cancer surgery
ACTRN12622000706774Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arginine in cancer (3 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Effect of influenza vaccine and immunonutrition on perioperative natural killer cell number and Effect of influenza vaccine and immunonutrition on perioperative natural killer cell activity. Started Sep 2022; status: completed.
02
Drugs
arginine
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12622000706774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000706774.